Τίτλος:
Prevalence and prognostic significance of anemia in patients with
congestive heart failure treated with standard vs high doses of
enalapril
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Anemia is common in patients with congestive heart failure
(CHF), although its etiology and pathophysiology remain largely
unexplained. The purpose of this study was to examine the prognostic
significance of a low hematocrit (Hct) in patients with CHF and the
possible role of angiotensin-converting enzyme inhibition in anemia
development.
Methods: Hct was measured at the time of enrollment of 160 patients with
CHF, mean age 56 12 years, in New York Heart Association (NYHA)
functional class 2.6 +/- 0.7 and with left ventricular ejection fraction
of 20 +/- 9%. They were randomized to standard (mean: 17.9 +/- 4.3
mg/day) or high (mean: 42 +/- 19.3 mg/day) doses of enalapril. The
follow-up duration was 2 years. Cox regression models were used to
identify prognostic factors, and correlations among individual variables
were tested.
Results: Mean baseline Hct was 42.7 +/- 5%. In multivariate analyses,
low Hct (p = 0.036), older age (p = 0.022) and low systolic blood
pressure (p = 0.032) were independent predictors of death within 2
years. A correlation was found between baseline Hct and NYHA class
(Spearman’s correlation coefficient: -0.183, p = 0.008). A significant
decrease in Hct from 43.2 +/- 4.9% at baseline to 40.7 +/- 4.4% at 2
years was observed in the group treated with high doses of enalapril (p
< 0.001).
Conclusions: Low baseline Hct predicted poor 2-year prognosis in
patients with CHF. Enalapril administered in high doses increased the
incidence of anemia in this population. The underlying pathophysiologic
mechanism and effects of maintaining a normal Hct on clinical outcomes
remain to be determined.
Συγγραφείς:
Terrovitis, JV
Anastasiou-Nana, MI
Alexopoulos, GP
Tsolakis,
EJ
Margari, ZJ
Drakos, SG
Tsagalou, EP
Papazoglou, P and
Efentakis, S
Nanas, JN
Περιοδικό:
The Journal of Heart and Lung Transplantation
Εκδότης:
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI:
10.1016/j.healun.2005.09.019
